Buy Rating Reaffirmed on Temporary Headwinds and Credible Turnaround Path Post-BD Acquisition
TipRanks (Tue, 17-Feb 6:35 AM ET)
Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus
Seeking Alpha News (Sun, 15-Feb 9:05 AM ET)
Market Chameleon (Mon, 9-Feb 3:59 AM ET)
Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses
PRNewswire (Mon, 9-Feb 8:40 AM ET)
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
PRNewswire (Mon, 9-Feb 8:40 AM ET)
Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results
PRNewswire (Mon, 9-Feb 6:30 AM ET)
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
PRNewswire (Tue, 27-Jan 9:25 AM ET)
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
PRNewswire (Tue, 27-Jan 9:25 AM ET)
PRNewswire (Mon, 26-Jan 1:29 PM ET)
Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call
PRNewswire (Tue, 20-Jan 1:00 PM ET)
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Waters trades on the NYSE stock market under the symbol WAT.
As of February 18, 2026, WAT stock price climbed to $327.53 with 1,304,262 million shares trading.
WAT has a beta of 0.75, meaning it tends to be less sensitive to market movements. WAT has a correlation of 0.11 to the broad based SPY ETF.
WAT has a market cap of $32.13 billion. This is considered a Large Cap stock.
Last quarter Waters reported $932 million in Revenue and $4.53 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.02.
In the last 3 years, WAT traded as high as $423.56 and as low as $231.90.
The top ETF exchange traded funds that WAT belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
WAT has underperformed the market in the last year with a price return of -11.4% while the SPY ETF gained +13.8%. WAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.3% and -13.6%, respectively, while the SPY returned +3.4% and -0.5%, respectively.
WAT support price is $314.41 and resistance is $328.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WAT shares will trade within this expected range on the day.